Miltenyi Biotec B.v. Co., Kg

Miltenyi Biotec, Gmbh

Michael Lutteropp

Stefan Miltenyi

Mario Assenmacher

Andrew Kaiser

Anne Richter

This disclosure provides a system for preventing or reducing side effects in a patent undergoing immunotherapy to remove diseased cells that express a target antigen: for example, by CAR T cell therapy. Side effects can ensue from concurrent depletion of hematopoietic cells bearing the same target antigen. A population of engineered hematopoietic cells is prepared by obtaining healthy hematopoietic cells from the patient or a third party donor, and using them to produce engineered hematopoietic cells. The engineered cells either do not express the target antigen, express it at a lower density, or express it in a modified form. The engineered hematopoietic cells are formulated for administration to the patient, whereupon they reconstitute hematopoietic cell function, thereby preventing or reducing the side effects.

Reducing side effects of immunotherapy using genetically modified hematopoietic cells

The invention provides a system that comprises pharmaceutical agents for use in immunotherapy for reducing the side-effects of an antigen-recognizing receptor against antigen-expressing non-target cells in an individual. The system includes an antigen-recognizing receptor that specifically recognizes an antigen on target cells and at least on one hematopoietic cell type in the individual. The antigen-recognizing receptor is exemplified by chimeric antigen receptors (CAR) be expressed on the surface of an immune effector cells. The system also includes hematopoietic cells resistant to recognition of the same antigen by the antigen-recognizing receptor.

Immunotherapy of cancer patients using CAR T or CAR NK cells combined with hematopoietic cells that have a modified or deleted target antigen

Combination of immune effector cells specific for a target antigen and hematopoietic calls that express the target antigen in an altered form

Immunotherapy method comprising administering a combination of immune effector cells and non-target hematopoietic cells

Combination of immune effector cells specific for a target antigen and hematopoietic cells that express the target antigen in an altered form

Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases

Growing community of inventors

Bergisch Gladbach, Germany

Michael Lutteropp